Articles by Catherine Kolonko

Latest Articles

Clinical Transplantation Trial Tests Use of Hepatitis C-Infected Kidney
  |  Catherine Kolonko
The Penn Medicine clinical trial uses kidneys from deceased donors who were infected with the hepatitis C virus. The first person in the trial received a kidney transplant in July and then underwent treatment with a regimen of Zepatier, one of the direct acting antiviral drugs approved recently to treat the virus.
VA Finds Success with Various Hepatitis C Regimens for Veterans
  |  Catherine Kolonko
The US Department of Veteran Affairs is finding success with modern DAAs.
High Frequency of Tregs After Curing Hepatitis C Could Enhance Liver Cancer Risk
  |  Catherine Kolonko
Even after eradicating hepatitis C with direct-acting antivirals, high frequency of Tregs could pose complications.
Court Orders Gilead to Pay Merck in Hepatitis C Drug Patent Lawsuit
  |  Catherine Kolonko
Merck just got $2.54 billion richer with the ruling of a federal jury.
Multi-Genotype Hepatitis C Drug Application Lands in Front of the FDA
  |  Catherine Kolonko
An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.
Head-to-Head Comparison of Two Hepatitis C Regimens Reveals Superior
  |  Catherine Kolonko
Elbasvir/grazoprevir (Zepatier) and sofosbuvir (Sovaldi) are used to treat hepatitis C around the world, but is one better than the other?
Frozen Shoulder Gets Quick Thaw in Diabetes Patients
  |  Catherine Kolonko
Extracorporeal shock therapy helped patients with diabetes improve their range of motion when suffering from "frozen shoulder" a study in Italy found.
Gilead Seeks FDA Approval for New Hepatitis C Treatment
  |  Catherine Kolonko
Gilead Sciences is seeking approval of a single tablet, 12-week combination hepatitis C regimen for patients of all genotypes previously treated for the disease with direct-acting antivirals.
Combination of Glecaprevir and Pibrentasvir Highly Effective Against Hepatitis C in Patients with Chronic Kidney Disease
  |  Catherine Kolonko
An investigational combination drug that targets all major genotypes of hepatitis C had a high success rate in a clinical trial of patients with severe chronic kidney disease, curing 98% of those who received 12 weeks of treatment.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$